SEC Comment Letter 0000000000-24-007966 to Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc.
Date: July 12, 2024 · CIK: 0000890821 · Accession: 0000000000-24-007966
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280721
Letter
July 12, 2024 Joseph Tucker, Ph.D. Chief Executive Officer Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Naples, FL 34103 Re:Enveric Biosciences, Inc. Registration Statement on Form S-3 Filed July 8, 2024 File No. 333-280721 Dear Joseph Tucker Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Bradley Wyatt, Esq.
Show Raw Text
July 12, 2024
Joseph Tucker, Ph.D.
Chief Executive Officer
Enveric Biosciences, Inc.
4851 Tamiami Trail N, Suite 200
Naples, FL 34103
Re:Enveric Biosciences, Inc.
Registration Statement on Form S-3
Filed July 8, 2024
File No. 333-280721
Dear Joseph Tucker Ph.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Bradley Wyatt, Esq.